AI Efficiency Gains And Behavioral Health Push Could Be A Game Changer For Elevance Health (ELV)

Elevance Health (ELV) has a market cap of $86.9B. Its stock rose 27.6% over 52 weeks, outperforming the S&P 500. Q2 2026 revenue was $49.8B, adjusted EPS $7.45. The company raised EPS and cash flow guidance. Analysts expect a 10.3% YOY EPS decline for 2026, but ELV has beaten estimates for four straight quarters. The consensus rating is 'Moderate Buy' with a mean price target of $445.71.

McKesson (MCK) fell 9.1% post-earnings despite a solid quarter. AdaptHealth (AHCO) missed revenue and EBITDA estimates, down 46.2%. Elevance Health (ELV) beat revenue and EPS estimates but lost customers, down 7.4%. Quest (DGX) topped expectations, up 12.6%.

CMS said Medicare Advantage payments to private insurers will rise 2.48% next year, implying about $13 billion in additional payments, and 4.98% after risk-score trends. UNH, HUM, CNC and ELV shares rose 5% to 11% in extended trading. CVS and MOH also gained, after a January proposal for a near-flat increase.

Elevance Health filed a complaint on July 27, 2026, in the US District Court for the Southern District of New York against managed care organization Hamaspik, Inc. and four of its own former employees. According to the filing, Hamaspik has run a "coordinated scheme" since December 2025 to hire the people who run Elevance's New York Managed Long-Term Care (MLTC) and Fully Integrated Dual Eligible Special Needs (FIDE) plans, which combine Medicare and Medicaid coverage in a single product.

Simply Wall St reports Elevance Health (ELV) paired Q2 results with higher full-year 2026 diluted EPS guidance of at least $20.10, despite lower quarterly net income. It cites ELV’s 90-day return of 12.36% and 1-year total shareholder return of 33.94%. A valuation narrative pegs fair value at $436.52 versus $389.09 prior close, implying undervaluation, contingent on Medicaid margins and medical cost trends.

Elevance Health (ELV) reported adjusted EPS of $7.45 versus $6.27 consensus and raised 2026 adjusted diluted EPS guidance to at least $27, with Medicare Advantage targeting at least a 2% operating margin. Shares fell 8.5% as Medicaid operating margin guidance stayed at -1.75%. Elevance said it will exit D.C. Medicaid and expects further Medicaid market exits in 12-18 months.